Presenting her research on 31 Conference of the European Society for Radiotherapy and Oncology [1], said Dr. Pernille Lassen, located in medical and radiation oncology and a researcher at Aarhus University Hospital, Denmark, that HPV-positive patients with advanced oropharyngeal cancer were. Significantly better control of the tumor at its primary site, disease-free survival after five years and overall survival than patients who were HPV negative.

Of the 181 patients 103 had HPV-positive tumors HPV-positive patients. Had better control of the tumor at its primary site , disease-specific survival , and overall survival .About the Studyis the patients in the research randomly assigned two doses groups of. Patient in every dose groups get one infusion of 300 mg HuMax-CD20 followed by 7 weekly infusions of either 500 or 1000 mg HuMax-CD20. Disease state is be assessed every 3 months to 24 months of.

Other articles from category "prevention":

Random articles